UBS Group’s China SXT Pharmaceuticals SXTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2 | Hold |
1
| – | – | ﹤0.01% | 10375 |
|
|
2025
Q4 | $356 | Hold |
1
| – | – | ﹤0.01% | 10010 |
|
|
2025
Q3 | $157 | Sell |
1
-416
| -100% | -$103K | ﹤0.01% | 9860 |
|
|
2025
Q2 | $108K | Buy |
417
+382
| +1,091% | +$109K | ﹤0.01% | 7170 |
|
|
2025
Q1 | $13.1K | Buy |
+35
| New | +$18.2K | ﹤0.01% | 8471 |
|
|
2024
Q4 | – | Sell |
-7
| Closed | -$4.14K | – | 9843 |
|
|
2024
Q3 | $6.33K | Sell |
7
-3
| -30% | -$3.25K | ﹤0.01% | 7979 |
|
|
2024
Q2 | $13.7K | Buy |
+10
| New | +$14.2K | ﹤0.01% | 7541 |
|
|
2024
Q1 | – | Sell |
-5
| Closed | -$11.8K | – | 9069 |
|
|
2023
Q4 | $25.4K | Buy |
5
+4
| +400% | +$11.1K | ﹤0.01% | 6948 |
|
|
2023
Q3 | $3.67K | Buy |
+1
| New | +$4.94K | ﹤0.01% | 7527 |
|
|
2023
Q2 | – | Sell |
-1
| Closed | -$5.1K | – | 9620 |
|
|
2023
Q1 | $5.1K | Buy |
+1
| New | +$13.5K | ﹤0.01% | 8088 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 9136 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 9066 |
|
|
2022
Q2 | – | Hold |
0
| – | -$15K | – | 10921 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 7847 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 8578 |
|
|
2021
Q2 | – | Hold |
0
| – | -$16K | – | 9811 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 7583 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 7020 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 5934 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 5642 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 6881 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 8392 |
|
|
2019
Q3 | – | Hold |
0
| – | -$7K | – | 8246 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 7251 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6550 |
|
Other funds holding SXTC
UBS Group's SXTC Position: Q1 2026 in Review
UBS Group held its China SXT Pharmaceuticals (SXTC) position steady in Q1 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #10375.
UBS Group first reported a position in SXTC in Q1 2023 and has held it in 10 quarters since. The position peaked at $108K in Q2 2025. 4 funds tracked by Wall St. Rank hold SXTC as of Q1 2026.
- UBS Group held 1 share of China SXT Pharmaceuticals worth $2 as of Q1 2026.
- UBS Group left its China SXT Pharmaceuticals share count unchanged in Q1 2026.
- China SXT Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10375 holding.
- UBS Group first reported a position in China SXT Pharmaceuticals in Q1 2023 and has held it in 10 quarters since.
- UBS Group's China SXT Pharmaceuticals position peaked at $108K in Q2 2025.
- 4 funds tracked by Wall St. Rank held China SXT Pharmaceuticals as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.